Europe
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2019 and its outlook for 2020.
Priority Review for BLA submission was granted by U.S. FDA for tafasitamab in combination with lenalidomide for relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) based on positive primary analysis data of L-MIND and Re-MIND studies
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
Bactiguard Holding AB, BACTI, has received orders from customers, including the Police Authority, at a total value of over SEK 20 million within the first few days of the launch of HYDROCYN aqua® on the Swedish market.
Companies strengthen their leadership teams and board with this week’s Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
PRESS RELEASES